CI vs IDXX: fair value comparison
The Cigna Group and IDEXX Laboratories, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, IDXX currently sits closer to the top of our discount ranking. IDXX carries the stronger quality grade.
| CI | IDXX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $278.88 | $554.99 |
| 12-month range | $244.41–$299.21 | $559.07–$728.97 |
| Sector rank | #32 of 113 Healthcare | #30 of 113 Healthcare |
| Quality grade | F | B |
| Momentum grade | D | — |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: CI fair value analysis · IDXX fair value analysis